No profile data available.
Ideaya Biosciences, Inc. (IDYA) is a healthcare company in the additional cancer treatment drugs industry, based in South San Francisco, United States, with about 145 full-time employees.
It reported revenue of $218.71 million for fiscal year 2025, up 3024.4% from fiscal year 2024, and net income of -$113.70 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $8.86 million. Its market capitalization was $3.48 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Ideaya Biosciences reported $218.71 million in revenue for fiscal year 2025, up 3024.4% from $7.00 million in fiscal year 2024. In Q2 2026 revenue was $8.86 million.
$3.48 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Erasca, Inc. (ERAS), Cogent Biosciences, Inc. (COGT), Relay Therapeutics, Inc. (RLAY), Arcus Biosciences, Inc. (RCUS).